Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
0.7709
-0.0581 (-7.01%)
At close: Jan 30, 2026, 4:00 PM EST
0.7601
-0.0108 (-1.40%)
After-hours: Jan 30, 2026, 7:48 PM EST
Decoy Therapeutics Employees
Decoy Therapeutics had 2 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,502,379
Market Cap
4.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2023 | 2 | -10 | -83.33% | 2 | 0 |
| Dec 31, 2022 | 12 | -4 | -25.00% | 12 | 0 |
| Dec 31, 2021 | 16 | 7 | 77.78% | 16 | 0 |
| Dec 31, 2020 | 9 | 1 | 12.50% | 7 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| GeoVax Labs | 17 |
| Abpro Holdings | 15 |
| Dermata Therapeutics | 8 |
| Aprea Therapeutics | 8 |
| Indaptus Therapeutics | 7 |
| Acurx Pharmaceuticals | 4 |
| Silo Pharma | 3 |
| 60 Degrees Pharmaceuticals | 3 |
DCOY News
- 18 days ago - Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PRNewsWire
- 24 days ago - Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics - GlobeNewsWire
- 6 weeks ago - Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - GlobeNewsWire
- 6 weeks ago - Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering - PRNewsWire